on the last thread someone kept saying that some of the 300k of consultant options had been exercised in jan.....THAT is incorrect as the qtr report of 30 april 2012 includes them
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%